The European Commission’s new president is on the defensive as allegations mount that he has a conflict of interest in the watchdog’s investigation into member states’ tax breaks to foreign companies.
Jean Claude Juncker, which began his position as European Commission President on November 1, says there is no conflict of interest in the case and has denied allegations that he encouraged so-called “sweetheart” deals with foreign companies when he was Prime Minister of Luxembourg. Luxembourg is one of the nations under investigation by the Commission as authorities examine whether those tax breaks constituted illegal state aid.
Just days after he took office, a slew of documents obtained by investigative journalists allegedly found major corporations like Pepsi and Ikea had inked deals with Luxembourg to save billions of dollars in taxes.
Juncker did not comment on the documents at the time. Luxembourg’s current Prime Minister, Xavier Buttel, stressed that all tax agreements were legal; now, Juncker is reiterating those claims.
The Commission’s competition arm is investigating Luxembourg, Irelad and Malta for their tax relationships with foreign companies. Critics say this constitutes illegal state aid and gives those firms an unfair financial advantage over their competitors. Companies have similarly come under fire for recent inversion mergers, in which the firms merge with another company for the intent of relocating their tax bracket abroad to benefit from lower tariffs.
Full content: BBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas